BlackRock Fund Advisors recently announced the acquisition of new stake in ATAI Life Sciences N.V. (NASDAQ:ATAI). The institutional investor has increased its shareholding in the Healthcare company by 5.93% to 1.42 million shares with purchase of 79581.0 shares. This fresh investment now brings its stake to 0.86% valued currently at $1.48 million. In addition, BMO Asset Management Corp. raised its holdings by 0.97 million to 0.97 million shares. And Morgan Stanley & Co. LLC has lifted its position by 97.71% or 0.43 million shares – to 0.88 million shares.
With over 4.67 million ATAI Life Sciences N.V. (ATAI) shares trading Tuesday and a closing price of $2.19 on the day, the dollar volume was approximately $10.24 million. The shares have shown a positive half year performance of 2.34% and its price on 01/09/24 gained nearly 8.42%. Currently, there are 165.94M common shares owned by the public and among those 114.08M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in ATAI Life Sciences N.V. are iShares Biotechnology ETF, SPDR S&P Kensho New Economies Com, and Morgan Stanley Instl. Fund Tr. -. iShares Biotechnology ETF owns 0.79 million shares of the company’s stock, all valued at over $0.83 million. The company sold 4422.0 shares recently to bring their total holdings to about 0.48% of the shares outstanding. Morgan Stanley Instl. Fund Tr. – bought 21812.0 shares to bring its total holdings to over 0.57 million shares at a value of $0.59 million. Morgan Stanley Instl. Fund Tr. – now owns shares totaling to 0.34% of the shares outstanding.
Shares of ATAI Life Sciences N.V. (NASDAQ: ATAI) opened at $2.06, up $0.04 from a prior closing price of $2.02. However, the script later moved the day high at 2.2300, up 8.42%. The company’s stock has a 5-day price change of 29.59% and 61.03% over the past three months. ATAI shares are trading 55.32% year to date (YTD), with the 12-month market performance up to 20.33% higher. It has a 12-month low price of $1.02 and touched a high of $2.39 over the same period. ATAI has an average intraday trading volume of 941.31K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 54.28%, 73.19%, and 37.26% respectively.
Institutional ownership of ATAI Life Sciences N.V. (NASDAQ: ATAI) shares accounts for 8.99% of the company’s 165.94M shares outstanding. Mutual fund holders own 3.06%, while other institutional holders and individual stakeholders account for 5.94% and 21.55% respectively.
It has a market capitalization of $363.56M and a beta (3y monthly) value of 0.84. The earnings-per-share (ttm) stands at -$0.42. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.67% over the week and 11.41% over the month.
Analysts forecast that ATAI Life Sciences N.V. (ATAI) will achieve an EPS of -$0.16 for the current quarter, -$0.18 for the next quarter and -$0.73 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.19 while analysts give the company a high EPS estimate of -$0.14. Comparatively, EPS for the current quarter was -$0.28 a year ago. Earnings per share for the fiscal year are expected to increase by 67.81%, and -131.78% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 6 brokerage firm advisors rate ATAI Life Sciences N.V. (ATAI) as a “Strong Buy” at a consensus score of 1.00. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 6 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ATAI, a number of firms have released research notes about the stock. Loop Capital stated their Buy rating for the stock in a research note on November 01, 2022, with the firm’s price target at $18.
